

Indices	CMP	%1D
Sensex	33149	-1.35
Nifty	10226	-1.30
BSE-Midcap	16917	-0.55
BSE-Smallcap	18228	0.1
SGX Nifty	10273	-0.04

Sector	CMP	%1D
Capital Goods	18445	-0.46
Realty	2445	1.09
Consumer Dur	21460	0.06
Metal	13902	-1.10
Oil & Gas	15927	-0.81
Teck	6080	-0.7

Index	FY17	FY18E	FY19E
Sensex EPS	1370	1550	1948
P/E	24	22	17
Nifty EPS	434	514	617
P/E	24	20	17

FII Trading activity in cash Rs Cr			
Date 30 November	Net	MTD	FY17
FII	-1500	-13512	-70968
DII	1202	9241	81547

Global Indices	Current Value	%1D
DowJones	24272	1.39
Nasdaq	6873	0.72
DAX	13023	-0.29
Nikkei 225	22740	0.07
FTSE 100	7326	-0.91
Hang Seng	29288	0.38
Shanghai	3317	-0.01
Straits Times	3448	0.42

Forex Rate		
USD/INR	64.64	0.20%
EUR/INR	76.58	0.15%
GBP/INR	86.97	0.54%
JPY/INR	57.58	-0.48%

G-Sec Yield	Price	Change%
1yr Bond Yield	6.40	0.06
10yr Bond Yield	7.06	0.53

Market Outlook

Indian markets likely to open flat on a constructive note taking strong cues on global market sentiments as well as on better than expected GDP numbers. Tracking the momentum, Markets should hold above 10220 level which acts as a major support and resistance is near 10480 in near terms. Expect markets to consolidate at the current level to make strong base for next possible upmove with a target of near 10600 levels.

Top Domestic News

- Biocon -European Medicines Agency Accepts Mktg Authorisation Application For Trastuzumab
- EMA Accepts Mktg Authorisation Application For Pegfilgrastim .Kiran Mazumdar Shaw told.EMA Has Accepted The Trastuzumab Application For Review. EMA Communication w.r.t Trastuzumab Does Not Mean An Approval. Target Action Date For US FDA Nod For Trastuzumab Is December 3
- No Technical Issues With Application With EMA For Trastuzumab
- Macro Data- October eight core ind growth unchanged at 4.7 percent (MoM) .Coal Sector Output At 3.9% Vs 10.6% (MoM) GDP Growth At 6.3% Vs 5.7% (QoQ) GDP Growth At 6.3% Vs 7.5% (YoY)
- M&M Fin QIP Book Launched- Offer Price: 435- 440/Sh .Issue Size: Up To `1,056 Cr (Approx \$164 m) At Upper End. Shares To Be Issued: Up To 2.4 Cr Shares
- Cadila Healthcare: Zydus Gets US FDA Nod For Pregabalin (25-300 mg) Capsules (Used To Treat Epilepsy, Neuropathic Pain, Fibromyalgia)
- Pfizer: Hospira Gets US FDA Nod For Epinephrine Injectable
- HDFC to sell part of its holding in HDFC AMC via IPO
- Reliance Power executes project agreements in respect of its 750 MW LNG Based Combined Cycle Power plant and LNG Terminal Project in Bangladesh
- Laurus Labs has received its maiden Tentative Approval from United States Food and Drug Administration (U.S FDA) for Tenofovir Disoproxil Fumarate Tablets 300mg
- Usha Martin - CARE Ratings has downgraded the rating of the Company's Short-term Bank Facilities from existing 'CARE A3' to 'CARE A4+
- LT Foods to strengthen presence in European market. Plans to invest \$20 million for overall branding and expansion.
- Allahabad Bank to sell 30% in Sampo Insurance.
- IIFL to pick up 330cr stake in M-Gaming co nazara Reliance Communications says Indian & Foreign Lenders

Global News

S&P closed at a record high and the Dow Jones Industrial Average broke above the 24,000 mark for the first time on Thursday. The Dow Jones Industrial Average rose 331.67 points, or 1.39 %, to 24,272.35, the S&P 500 gained 21.51 points, or 0.82 %, to 2,647.58. The Nasdaq added 49.63 points, or 0.73 %, to 6,873.97. Reuters reported. Asian markets rose in early trade on Friday, after US stocks rallied overnight at the increasing likelihood that the Senate might pass a bill aimed at overhauling the US tax code. The ASX 200 topped 6,000 after the first hour of trade. The index rose 0.59 %. Japan's Nikkei 225 was up 0.97 % to 22,945.27, while the Topix index gained 0.72 %. Across the Korean Strait, the Kospi gained 0.29 %, CNBC reported.

NSE Top Gainers

Script	LTP	%1D
GAIL	467.00	1.05
BOSCHLTD	20275.05	1.04
BAJAJAUTO	3335.00	0.58
NTPC	183.00	0.55
HINDPETRO	418.25	0.46

NSE Top Losers

Script	LTP	%1D
UPL	727.00	-3.36
HINDALCO	239.80	-2.88
KOTAKBANK	1000.55	-2.50
AXISBANK	535.80	-2.49
RELIANCE	922.50	-2.48

BSE Top Gainers

Script	LTP	%1D
RTNPOWER	8.51	9.95
MCLEODRUSS	234.60	7.12
DEN	99.40	7.00
SOBHA	622.80	5.45
BOMDYEING	221.35	4.73

BSE Top Losers

Script	LTP	%1D
SREINFRA	102.15	-6.16
SUZLON	13.95	-3.79
ADANITRANS	183.40	-3.70
APOLLOTYRE	250.70	-3.13
MMTC	74.90	-3.10

Technical View



Bank Nifty has opened with a gap up and held on the momentum and made a fresh new high. Bank Nifty has today given a break out from a Decending Channel Pattern. The target for this pattern is 26786.5. But it is adviced to watch 25630 & 26180 as both are strong resistance levels. The gap ups, the 13 EMA is above 21 EMA, MACD is also giving a buy signal and the RSI is not in over bought zone. All of them indicate a strong up move rally.

Msearch

MEHTA



Disclaimer: The views expressed / recommendations made in this report are based on Technical Analysis techniques and could be at variance with the company's / group's views based on fundamental research. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options another derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MEHTA EQUITIES LTD, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MEHTA EQUITIES LTD. The views expressed are those of the analyst and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MEHTA EQUITIES LTD to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478
MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India
Tel: +91 22 6150 7101, Fax: +91 22 6150 7102

Email: info@mehtagroup.in, Website: www.mehtagroup.in